Analysts voiced no little skepticism in 2014 when Celgene Corp. acquired privately held Nogra Pharma Ltd. to get its hands on GED-0301 (mongersen), a phase III-ready, oral antisense DNA oligonucleotide targeting the Smad7 protein to treat moderate to severe Crohn’s disease (CD) and related indications.